Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|January 14, 2000
Making sense of antisenseB R Yacyshyn, W R ShanahanMolecular Biotechnology|November 11, 1999
Preclinical and clinical pharmacology of antisense oligonucleotidesE G Marcusson, B R Yacyshyn, W R Shanahan, et al.Immunology and Cell Biology|August 1, 1993
Activated CD19+ B cell lamina propria lymphocytes in ulcerative colitisB R YacyshynBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 21, 2007
New biotechnological therapies for Crohn's disease: where are we now?B R YacyshynGastroenterology|June 3, 1998
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's diseaseB R Yacyshyn, M B Bowen-Yacyshyn, L Jewell, et al.Gut|June 22, 2002
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's diseaseB R Yacyshyn, W Y Chey, J Goff, et al.Diseases of the Colon and Rectum|October 5, 2001
The concept and application of antisense oligonucleotidesB R Yacyshyn, S T CrookeGastroenterology|January 1, 1995
CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeabilityB R Yacyshyn, J B MeddingsDigestive Diseases (Basel, Switzerland)|March 30, 2001
Critical review of acid suppression in nonvariceal, acute, uppergastrointestinal bleedingB R Yacyshyn, A B ThomsonGut|December 1, 1993
Expression of CD45RO on circulating CD19+ B-cells in Crohn's diseaseB R Yacyshyn, L M PilarskiPageof 3